BCRX

BioCryst Pharmaceuticals, Inc. (BCRX) Management Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Leadership Execution

Management is operating with improving cash generation, as free cash flow remains positive at $507.8M TTM and free cash flow margin is supported by low capex intensity.

Execution remains mixed because profitability is still negative, with EBIT margin at -32.8% and net margin at -40.9% TTM.

Balance sheet flexibility is acceptable, with a current ratio of 2.32 and net debt to EBITDA of -0.84, indicating net cash rather than leverage pressure.

Capital Allocation

Capital allocation appears disciplined on capex, with capex only 0.3% of revenue and capex coverage extremely strong.

The company is still not returning capital to shareholders, with dividend yield and payout ratio both at 0.

Stock-based compensation remains meaningful at 13.0% of revenue, which is a continuing dilution consideration.

Governance Incentives

No fresh governance or compensation disclosures were provided this month, so the prior view is unchanged.

Management quality is still judged primarily through operating and cash-flow execution rather than new board or incentive developments.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on BioCryst Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →